The full approval of Eisai and Biogen’s Leqembi clears the way for broader Medicare coverage of the treatment, which has been limited.| Alzheimer's News Today
Biogen is discontinuing development and commercialization of its controversial Alzheimer's treatment Aduhelm to focus its efforts on Leqembi.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
The U.S. FDA has approved monthly maintenance dosing for Leqembi, a treatment for early Alzheimer’s disease.| Alzheimer's News Today
Under-the-skin injections worked better in trial than the approved Leqembi formulation in clearing harmful amyloid plaques in Alzheimer's.| Alzheimer's News Today
A decision from the FDA on once-monthly maintenance dosing of Leqembi in early Alzheimer's is expected by Jan. 25, 2025.| Alzheimer's News Today
Eisai has started a rolling application seeking U.S. FDA approval of an under-the-skin injection version of Leqembi for early Alzheimer’s.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today